Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid. 海报 Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid. webdev2019 年 8 月 22 日
What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria” Poster What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria” webdev2019 年 8 月 22 日
T4.1 – Setting the framework for database and development of this database Poster T4.1 – Setting the framework for database and development of this database webdev2019 年 8 月 22 日
Modelling Toxicodynamic Feedback is Critical in Recovering Toxicokinetics in Acetaminophen Overdose Poster Modelling Toxicodynamic Feedback is Critical in Recovering Toxicokinetics in Acetaminophen Overdose webdev2019 年 8 月 9 日
Development and Performance Evaluation of a semi-mechanistic PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eye Poster Development and Performance Evaluation of a semi-mechanistic PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eye webdev2019 年 6 月 24 日
Transporter inhibition: modelling in-vitro Transwell Assays Poster Transporter inhibition: modelling in-vitro Transwell Assays webdev2019 年 6 月 24 日
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper 利用 QSP 优化免疫肿瘤药物发现与开发 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…webdev2019 年 6 月 19 日
Pirana Modeling Workbench Brochure Pirana 建模工作平台 Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…webdev2019 年 5 月 28 日
Precision Dosing in Clinical Medicine: Present and Future Publication Precision Dosing in Clinical Medicine: Present and Future webdev2018 年 7 月 20 日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond Publication Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…Jieun Choe2018 年 6 月 2 日